Laparoscopic intracavitary catheterization combined with bleomycin quadruple sclerotherapy for retroperitoneal lymphatic malformations: a single-center case series - Summary - MDSpire
Advertisement
Laparoscopic intracavitary catheterization combined with bleomycin quadruple sclerotherapy for retroperitoneal lymphatic malformations: a single-center case series
To evaluate the feasibility, safety, and efficacy of laparoscopic intracavitary catheterization combined with bleomycin quadruple sclerotherapy for massive retroperitoneal lymphatic malformations (rLMs), emphasizing its innovative approach.
Key Findings:
All patients completed treatment without conversion to open surgery or adjacent organ injury.
Mean operation time was 128 ± 25 min (range: 80-200 min), with blood loss of 2 ± 2 mL and cyst fluid aspiration of 135 mL.
Patients ambulated within 6 hours, resumed oral intake at 20 ± 3 hours, and had a mean hospital stay of 12 ± 6 days (range: 6-18 days).
One patient experienced a grade I complication (self-limiting abdominal discomfort), with no higher-grade complications.
All patients achieved clinical cure with no recurrence during a median follow-up of 46 months.
Interpretation:
Laparoscopic intracavitary catheterization combined with bleomycin quadruple sclerotherapy is a minimally invasive and effective strategy for managing massive rLMs, potentially transforming treatment protocols.
Limitations:
Small sample size of only 5 patients.
Retrospective nature may introduce bias, including the absence of a control group.
Conclusion:
The study presents a standardized minimally invasive protocol for treating massive rLMs, demonstrating minimal trauma and a favorable complication profile, with potential implications for clinical practice.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
Patients with preoperative vitamin D deficiency had higher postoperative pain scores and opioid use after mastectomy, including more than triple the odds of moderate to severe pain within 24 hours of surgery.
